Jaguar Health(JAGX)2024-08-13 12:13Financial Performance - The combined net revenue for Q2 2024 was approximately 2.64 million, reflecting a 15% increase from Q1 2024 and a 1% increase from Q2 2023[5] - The loss from operations decreased to 8.1 million in Q2 2023, marking a 13% improvement[6] - Net loss attributable to common shareholders decreased to 12.1 million in Q2 2023, a reduction of approximately 28%[8] - Non-GAAP recurring EBITDA for Q2 2024 was a net loss of 7.7 million in Q2 2023[9] - The total cost of product revenue decreased by approximately 0.50 million in Q2 2023 to 0.6 million to $3.7 million in Q2 2024, primarily due to winding down activities related to the phase 3 OnTarget clinical trial[6] - An import permit for crofelemer has been granted for a proof-of-concept trial in pediatric patients in Abu Dhabi[3] - The company is exploring possible approval pathways for crofelemer in breast and lung cancer based on phase 3 trial results[4] - Results from investigator-initiated and IND proof-of-concept studies of crofelemer for MVID and SBS with intestinal failure are anticipated to be available by the end of 2024 and throughout 2025[18] - The company may engage in discussions with the FDA regarding the clinical outcome signals from the OnTarget trial[18] - An approval pathway may exist to make crofelemer available to breast and lung cancer patients for CTD[18] - Published data from clinical investigations of crofelemer in MVID and SBS could support early patient access in specific EU countries[18] Product Launch - The company plans to commercially launch Gelclair, its third prescription product, in October 2024[4] - The company expects to begin the commercial launch of Gelclair in October 2024[18]